Incyte Corporation (INCY) Stock Forecast
Data as of Jun 16, 2026Healthcare · Current price $99.97 (-1.98%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Feb 11, 2026 | Stephen Willey | Stifel Nicolaus | $120.00 | +20.0% |
| Feb 6, 2026 | Allison Bratzel | Piper Sandler | $110.00 | +10.0% |
| Jan 5, 2026 | Stephen Willey | Stifel Nicolaus | $119.00 | +19.0% |
| Dec 24, 2025 | Srikripa Devarakonda | Truist Financial | $103.00 | +3.0% |
| Dec 8, 2025 | Derek Archila | Wells Fargo | $116.00 | +16.0% |
| Dec 8, 2025 | Salim Syed | Mizuho Securities | $121.00 | +21.0% |
| Nov 4, 2025 | Allison Bratzel | Piper Sandler | $102.00 | +2.0% |
| Oct 29, 2025 | Derek Archila | Wells Fargo | $97.00 | -3.0% |
| Oct 29, 2025 | Peter Lawson | Barclays | $101.00 | +1.0% |
| Oct 30, 2024 | Aaron Kessler | Seaport Global | $200.00 | +100.1% |
| Oct 30, 2024 | Jay Olson | Oppenheimer | $82.00 | -18.0% |
| Oct 30, 2024 | David Lebowitz | Citigroup | $97.00 | -3.0% |
| Oct 29, 2024 | Kelly Shi | Jefferies | $84.00 | -16.0% |
| Oct 29, 2024 | Tazeen Ahmad | Bank of America Securities | $90.00 | -10.0% |
| Sep 30, 2024 | Andy Chen | Wolfe Research | $84.00 | -16.0% |
| Sep 16, 2024 | Tazeen Ahmad | Bank of America Securities | $68.00 | -32.0% |
| Sep 16, 2024 | Salveen Richter | Goldman Sachs | $60.00 | -40.0% |
| Aug 18, 2024 | David Lebowitz | Citigroup | $92.00 | -8.0% |
| Jul 31, 2024 | Brian Abrahams | RBC Capital | $66.00 | -34.0% |
| Jul 26, 2024 | Jay Olson | Oppenheimer | $81.00 | -19.0% |
Top Analysts Covering INCY
INCY vs Sector & Market
| Metric | INCY | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.30 | 2.24 | 2.40 |
| Analyst Count | 20 | 8 | 19 |
| Target Upside | +0.9% | +11475.0% | +17.1% |
| P/E Ratio | 14.12 | 3.90 | 31.64 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-06-30 | $1.29B | $1.36B | $1.42B | 12 |
| 2026-09-30 | $1.38B | $1.44B | $1.51B | 10 |
| 2026-12-31 | $5.48B | $5.57B | $5.76B | 17 |
| 2027-03-31 | $1.28B | $1.35B | $1.41B | 6 |
| 2027-06-30 | $1.43B | $1.50B | $1.56B | 6 |
| 2027-09-30 | $1.49B | $1.56B | $1.63B | 6 |
| 2027-12-31 | $1.61B | $1.69B | $1.77B | 6 |
| 2028-03-31 | $1.34B | $1.41B | $1.47B | 6 |
| 2028-06-30 | $1.55B | $1.62B | $1.70B | 5 |
| 2028-09-30 | $1.48B | $1.55B | $1.62B | 5 |
| 2028-12-31 | $1.49B | $1.57B | $1.64B | 6 |
| 2029-12-31 | $4.39B | $4.59B | $5.13B | 11 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-06-30 | $1.62 | $1.77 | $1.95 | 12 |
| 2026-09-30 | $1.91 | $2.03 | $2.15 | 9 |
| 2026-12-31 | $6.68 | $7.35 | $7.65 | 15 |
| 2027-03-31 | $1.75 | $1.86 | $1.97 | 4 |
| 2027-06-30 | $2.08 | $2.22 | $2.35 | 5 |
| 2027-09-30 | $2.29 | $2.44 | $2.58 | 8 |
| 2027-12-31 | $2.78 | $2.96 | $3.13 | 4 |
| 2028-03-31 | $1.86 | $1.98 | $2.09 | 5 |
| 2028-06-30 | $2.38 | $2.53 | $2.68 | 7 |
| 2028-09-30 | $2.16 | $2.30 | $2.44 | 10 |
| 2028-12-31 | $2.03 | $2.17 | $2.29 | 5 |
| 2029-12-31 | $3.47 | $3.67 | $4.24 | 4 |
Frequently Asked Questions
What is the analyst consensus for INCY?
The consensus among 20 analysts covering Incyte Corporation (INCY) is Buy with an average price target of $108.90.
What is the highest price target for INCY?
The highest price target for INCY is $200.00, set by Aaron Kessler at Seaport Global on 2024-10-30.
What is the lowest price target for INCY?
The lowest price target for INCY is $48.00, set by Evan Seigerman at BMO Capital on 2024-07-02.
How many analysts cover INCY?
20 analysts have issued ratings for Incyte Corporation in the past 12 months.
Is INCY a buy or sell right now?
Based on 20 analyst ratings, INCY has a consensus rating of Buy (2.30/5) with a +0.9% upside to the consensus target of $108.90.
What are the earnings estimates for INCY?
Analysts estimate INCY will report EPS of $1.77 for the period ending 2026-06-30, with revenue estimated at $1.36B.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.